---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344584"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2026-08-11T20:05:19+00:00"
generated_at: "2026-08-11T20:07:59.479159+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Erasca Q2 net loss $44.1M; ERAS-0015 57% uORR in PDAC; raises $632M

## Summary
- Q2 2026 net loss $44.1M ($0.14/sh) vs $33.9M ($0.12/sh) in Q2 2025; R&D expense $35.9M vs $21.2M.
- Cash $384.3M at June 30, 2026; July upsized offering raised ~$632.5M gross, Jan 2026 offering ~$258.8M.
- ERAS-0015 at 32mg QD showed 57% uORR8wk in 2L+ KRAS G12X PDAC; no DLTs, no tx-related discontinuations, 100% median dose intensity.
- Plans for three registration-enabling trials: 2L+ NSCLC (H1 2027), 1L PDAC (2027), RASm NSCLC (H2 2027-H1 2028).
- Appointed Charles Fuchs as president of R&D and David Chonzi as SVP global pharmacovigilance in August 2026.

## SEC filing metadata
- accession: 0001193125-26-344584
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2026-08-11T20:05:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/0001193125-26-344584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/eras-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344584
- JSON: https://secwatch.observer/filing/0001193125-26-344584.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.